Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

Banning PBM spread pricing in Medicaid-managed care ... We sell different types of products and services to both investment professionals and individual investors. These products and services ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are ...

BofA sees 2025 challenges for healthcare tech and distributors but upgrades Cardinal Health and Henry Schein, highlighting ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...